VERIGENE® Gram-Negative Blood Culture Test
Help patients recover from bacteremia more quickly
VERIGENE® Gram-Negative Blood Culture Test allows for proven clinical impact and outstanding economic value coupled with the right assay design.
Powered by Bioz
Disease state
Approximately 250,000 US patients are diagnosed with bloodstream infections (BSIs) annually. Sepsis caused by a BSI has an average mortality rate of 16-40% and delay in appropriate treatment can add additional risk for the patient. Sepsis also has the unfortunate distinction of being the most expensive cause of hospitalization in the US at more than $20B per year.
Gram-negative bacteremia accounts for approximately 30% of all positive blood cultures. Each pathogen and associated resistance gene often requires therapeutic adjustments from more generalized empiric therapy.
Sepsis is a disease associated with high mortality
The value of VERIGENE® Gram-Negative Blood Culture Test (BC-GN)
Empower clinicians to rapidly optimize treatment for bacteremia
Proven clinical impact
Identification of routine pathogens allows for rapid treatment optimization backed by years of peer-reviewed studies.
Outstanding economic value
Panel selection based on Gram stain helps improve diagnostic stewardship while keeping operational costs under control.
The right assay design
Non-amplified molecular chemistry helps minimize false results while allowing for universal collection media.
How the VERIGENE® Gram-Negative Blood Culture Test works
VERIGENE® BC-GN is a multiplexed in vitro diagnostic test for the detection and identification of pathogenic gram-negative bacteria. Subculturing is necessary for antimicrobial susceptibility testing and identification of organisms not detected by the test.
Sample-to-answer
Consumables arrive at the laboratory ready to use with no further reagent preparation.
Time to results is 3X faster
Adding the VERIGENE result to traditional, standard-of-care workflow provides clinicians the opportunity to make targeted treatment decisions two hours after Gram stain.
VERIGENE® Gram-Negative Blood Culture Kit
The VERIGENE® Bloodstream Infection (BSI) portfolio provides accurate test results in a clinically meaningful timeframe.
Product |
Pathogen |
Resistance Gene |
|---|---|---|
| Species | Escherichia coli* | CTX-M (ESBL) |
| Klebsiella pneumoniae | IMP | |
| Klebsiella oxytoca | KPC | |
| Pseudomonas aeruginosa | NDM | |
| . | OXA | |
| Serratia marcescens | VIM | |
| Genus | Acinetobacter spp. | |
| Citrobacter spp. | ||
| Enterobacter spp. | ||
| Proteus spp. |
'* BC-GN will not distinguish Escherichia coli from Shigella spp. (S. dysenteriae, S. flexneri, S. boydii, and S. sonnei).
For use with the VERIGENE® System
The VERIGENE® System rapidly and accurately detects infectious pathogens and their associated drug-resistance markers.
Delivery of this time-critical information allows clinicians to provide targeted patient care more quickly, potentially leading to improved patient outcomes and lower treatment costs.
VERIGENE’s ease of use makes it a valuable system for use in both hospital-based and reference laboratories.
VERIGENE® Gram-Negative Blood Culture Kit ordering info
Part Name |
Kit Size |
Registration Status |
Part Number |
|---|---|---|---|
|
VERIGENE® Gram-Negative Blood Culture Test (BC-GN) Kit |
20 BC-GN Test Cartridges and 20 Extraction Trays |
IVD | 20-005-021 |
|
VERIGENE® Gram-Negative Blood Culture Test (BC-GN) Utility Reagent Kit |
20 BC-GN Utility Trays |
IVD | 20-012-021 |